These findings suggest that the ability of cabozantinib to promote ferroptotic cytotoxicity in NSCLC cells is mechanistically linked to its suppression of the STAT3/MCL1 signaling axis, a property not shared by the other VEGFR TKIs tested. Here, STAT3 is linked to non-small cell lung carcinoma.